Celgene 2018 revenue forecast shy of estimates, shares fall

(Reuters) - Celgene Corp , which has announced a deal to buy Impact Biomedicines, on Monday forecast 2018 total revenue that fell short of analysts' estimates, sending the U.S. biotech company's shares down 2 percent.

from Reuters: Health News http://ift.tt/2qGNPif